Takeda Pharmaceutical Korea announced on the 18th that it has appointed Kwang-kyu Park as the new Chief Executive Officer (General Manager). Park is an expert with over 20 years of experience in global pharmaceuticals.
According to Takeda Pharmaceutical Korea, Kwang-kyu Park, the new Chief Executive Officer, led new drug introductions, organizational innovation, and stakeholder collaboration at global pharmaceutical companies such as Bristol-Myers Squibb (BMS) Korea, AstraZeneca Korea, and Merck (MSD) Korea. Recently, he served as the head of the liver disease division at Gilead Sciences Korea, contributing to the improvement of the domestic liver disease treatment environment and patient-centered healthcare innovation. Park graduated from Kyunghee University with a degree in pharmacy and earned a Master of Business Administration (MBA) from Seoul National University.
The new Chief Executive Officer Park said, "Takeda Pharmaceutical Korea has pursued continuous growth while realizing patient-centered innovation in a rapidly changing healthcare environment," adding, "We will continue to seek various solutions to accelerate the introduction of innovative treatments and ensure that healthcare professionals and patients have optimal treatment opportunities."